University of Florida Health, Jacksonville, FL
Steven Badami, Kimberly Boldig, Abhinav Rohatgi
Background: Advances in genomic mutation profiling have helped strengthen the management of cancer, however access to these advances can be challenging in hospitals serving majorly low-income neighborhoods due to socioeconomic factors. In a retrospective cohort study at our safety net hospital, serving lower socioeconomic populations, we identified the real-world uptake of tissue based next-generation sequencing (NGS) and liquid biopsy (ctDNA) in treated oncology patients. Methods: Records from 85 solid tumor patients treated at UF Health were evaluated for specific demographics and for completion of liquid biopsies and also NGS of patients’ tumors. 25 of those patients had completed liquid biopsies and were included. Genomic mutation profiles were stratified by liquid biopsies and whether or not NGS was completed. Concordance of multiple variant mutations between NGS and liquid biopsy were analyzed to determine if both tests were actionable. Results: Of these 85 patients, 25 obtained genomic mutation profiles from liquid biopsies with 10 also obtaining profiles from NGS. Of the profiled tumors, 64% contained actionable variant mutations for a specific therapy. Comparative analysis between patients with liquid biopsies and NGS revealed a concordance rate of 70% in variant mutation identification and 20% concordance rate in actionable variant mutations. Additionally, of the patients who received only liquid biopsies, 52% contained variant mutations that were actionable. Conclusions: Our data shows that 64% of patients with liquid biopsy and 70% with NGS had actionable mutations. The low concordance in actionable mutations between NGS and liquid biopsy suggests that both tests should be done to inform cancer management. Our data demonstrates that hospitals that serve low-income populations have limited access in obtaining genomic mutation profiling through liquid biopsies or NGS due to the socioeconomic challenges our patients face. Cancer centers in safety-net hospitals should address challenges to obtaining actionable data provided by genetic mutation profiling to inform treatment options for those patients.
Number of patients (n) | NGS (n) | Actionable Mutations (n) | Concordant Mutations (n) | Concordant and Actionable Mutations (n) | Actionable mutations found on Liquid Biopsy (n) | Non-Actionable mutations found on Liquid Biopsy (n) | Actionable mutations found on Tissue NGS (n) | Non-Actionable mutations found on Tissue NGS (n) | |
---|---|---|---|---|---|---|---|---|---|
White | 14 | 5 | 9 | 3 | 2 | 7 | 12 | 5 | 3 |
Black | 10 | 4 | 6 | 3 | 0 | 5 | 9 | 1 | 4 |
Medicaid | 12 | 3 | 8 | 2 | 1 | 6 | 9 | 3 | 2 |
Medicare | 13 | 7 | 8 | 5 | 1 | 7 | 13 | 4 | 6 |
Liquid Biopsy Only | 15 | 0 | 6 | 0 | 0 | 6 | 13 | 0 | 0 |
Liquid biopsy and NGS | 10 | 10 | 9 (90%) | 7 (70%) | 2 (20%) | 6 (60%) | 9 (90%) | 7(70%) | 8(80%) |
Whole Cohort | 25 | 10(40%) | 16 (64%) | 7 (28%) | 2 (8%) | 13 (52%) | 22(88%) | 7(28%) | 8(32%) |
n = number of patients.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Emmanuella Faith Amoako
2023 ASCO Annual Meeting
First Author: Zeng Qingxin
2023 ASCO Annual Meeting
First Author: Kamil Taneja
2024 ASCO Genitourinary Cancers Symposium
First Author: Kenneth Barker